Event Type
Disclosure
Voluntary
Variant
8-K
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchang
Other Events. On January 5, 2026, Genelux reported interim results from two ongoing trials evaluating systemic (intravenous) administration of Olvi-Vec in patie
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated January 5, 2026 104 Cover Page Interactive Data File (embedded